What’s New

We share news about new product features, our thoughts on recent developments at MedaSystems or in the industry at large. Scroll down for a chronological view, or jump to posts using the categories to the left.

Aimee Caton 8/28/26 Aimee Caton 8/28/26

Expanding Access Worldwide: How MedaSystems Helps Bring Therapies to Patients Across the Globe

Expanded Access Programs help patients with serious or life-threatening conditions access investigational therapies when other treatment options are limited. Discover how MedaSystems helps pharmaceutical and biotechnology organizations centralize, automate and scale Expanded Access programs across patients, therapies and markets worldwide.

Aimee Caton 7/9/26 Aimee Caton 7/9/26

The Biggest Challenges Facing Expanded Access Programs—and How Leading Pharmaceutical Companies Are Responding

As Expanded Access programs become more global and complex, pharmaceutical companies need scalable ways to manage requests, maintain compliance, and support patients faster.

Aimee Caton 5/27/26 Aimee Caton 5/27/26

Investigator-Initiated Studies (IIS) Trends in 2026

Investigator-Initiated Studies (IIS) are entering a transformative phase in 2026. As pharmaceutical companies, biotech firms, academic medical centers, and healthcare systems adapt to changing research demands, IIS programs are becoming more strategic, data-driven, patient-centered, and digitally enabled.

Aimee Caton 4/8/26 Aimee Caton 4/8/26

Why Expanded Access Programs Often Originate in Medical Affairs

Expanded Access Programs (EAPs) - also known as compassionate use—play a critical role in bridging the gap between clinical development and patient need.